基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施

doi:10.19803/j.1672-8629.20230505

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (10): 1095-1098.
DOI: 10.19803/j.1672-8629.20230505

• 上市后监测方法与评估体系研究专栏 • 上一篇下一篇

基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施

刘红亮¹, 王青², 侯永芳^1,*

¹国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076;
²清华大学药物警戒信息技术与数据科学创新中心,北京 100084

收稿日期:2023-08-18 出版日期:2023-10-15 发布日期:2023-10-16
通讯作者: ^*侯永芳,男,正高级工程师,药品不良反应监测。E-mail: houyongfang@cdr-adr.org.cn
作者简介:刘红亮,男,硕士,主管药师,药品不良反应监测。
基金资助:
国家重点研发计划（2020YFC2005501）

Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data

LIU Hongliang¹, WANG Qing², HOU Yongfang^1,*

¹Center for Drug Reevaluation, NMPA/NMPA Key Laboratory for Research and Evaluation of Pharmacovigilance, Beijing 100076, China;
²Research Center for Pharmacovigilance IT and Data Science, Tsinghua University, Beijing 100084, China

Received:2023-08-18 Online:2023-10-15 Published:2023-10-16

摘要/Abstract

摘要： 目的基于真实世界数据,设计并实施老年常见病多重用药风险数据管理平台,为开展全国老年常见病多重用药风险监测与管控工作提供系统性的支持和参考。方法以构建回顾性数据库、前瞻性数据库管理平台的思路,基于面向医疗机构的老年常见病多重用药风险监测数据标准,研发建立分布式数据管理平台。结果和结论 该平台部署在相关医疗机构或者区域性医疗信息化平台上,可实现数据提供伙伴的数据汇集、数据抽提和转换、数据查询、分析、统计等功能,作为基础性分析环境接收老年常见病多重用药任务的分析程序,可在本地完成单中心的老年常见病多重用药分析任务,并提供分析结构的查询、递交功能,为老年常见病多重用药任务提供基础数据分析环境。

关键词: 老年, 常见病, 多重用药, 数据管理, 平台

Abstract: Objective To design and implement a database management platform for polypharmacy risk in common geriatric diseases based on real-world data, and to provide systematic support and reference for the risk monitoring and control of multiple drug use for common elderly diseases in China. Methods Based on the monitoring data standard of polypharmacy risk for common elderly diseases for medical institutions, a distributed data management platform was developed and established with the idea of building retrospective database and prospective database management platform. Results and Conclusion It is deployed in relevant medical institutions or regional medical information platforms to achieve data collection, data extraction and transformation, data query, analysis, statistics and other functions of data providing partners as a basic analysis environment. And it receives the analysis program of polypharmacy use for common diseases of the elderly, completes the polypharmacy analysis task of common diseases of the elderly in a single center in the local, and provides the query and submission function of the analysis structure. Through the construction of the data management platform, it could provide a basic data analysis environment for polypharmacy tasks for common geriatric diseases

Key words: elderly, common diseases, polypharmacy, data management, platform

中图分类号:

R954

刘红亮, 王青, 侯永芳. 基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施[J]. 中国药物警戒, 2023, 20(10): 1095-1098.

LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098.

参考文献

[1] NMPA. Circular on the Publication of the Guiding Principles on Real World Evidence to Support Drug Development and Review (Trial)[EB/OL].(2020-01-07)[2023-06-18]. https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20200107151901190.html.
[2] JIANG X, LIU LR, ZHU H, et al.Enlightenment of foreign drug management systems on the drug management of the elderly in China[J].Herald of Medicine(医药导报), 2020, 39(8): 1166-1169.
[3] SHU T, CHEN WG, HOU YF, et al.Research and application of the sentinel hospital pharmacovigilance system based on HIS[J].China Pharmacy(中国药房), 2017, 28(25): 3468-3471.
[4] HOU YF, SONG HB, LIU HL, et al.Practice and discussion on active surveillance by China hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(4): 212-214.
[5] WANG LL, YANG Y, WANG SL.Application of the US FDA sentinel system and enlightenmen[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(2): 81-87.
[6] LIU HL, ZHENG MJ, LI XL, et al.Overview of implementation of E2B (R3) guidelines by ICH founding regulatory members[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 594-596.
[7] NMPA. Regional Implementation Guide for Individual Case Safety Reporting E2B(R3).[EB/OL].(2019-11-22)[2023-06-18]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/gzwj/gzwjzh/20191122091301498.html.
[8] HOU YF, DONG D, XIONG WY, et al.Developement of ICSR E2B Guideline[J].Chinese Journal of Pharmacovigilance(中国药物警戒), 2018, 15(3): 144-146.
[9] ZHANG RX, LIU QY, WANG HL, et al.Practice of a pharmacist-delivered service model and situation of drug-related problems among chronic elderly patients with polypharmacy in our hospital[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2022, 25(7): 630-634.
[10] National Key Research and Development Program (2018YFC2002400) Subject Groups. Expert consensus on safety management of multi-drug administration in elderly patients with co-morbidities in the elderly[J]. Chinese Journal of Health Care and Medicine(中华保健医学杂志), 2021, 23(5): 548-554.
[11] LI XY.Discussion on management mode of older adults with multimorbidity[J].Chinese Journal of Geriatric Heart Brain and Vessel Diseases(中华老年心脑血管病杂志), 2022, 24(5): 449-452.
[12] TANG YC, GU PY JIN S, et al. Clinical observation of polypharmacy in the elderly aged over 80 years[J]. Chinese Journal of Clinical Healthcare(中国临床保健杂志), 2018, 21(2): 156-159.
[13] National Health and Health Commission of the People's Republic of China. Health Industry Standard of the People's Republic of China(中华人民共和国卫生行业标准)[S/OL]. (2023-03-07)[2023-08-10]. http://www.nhc.gov.cn/cms-search/downFiles/864c23896af04e9fbaaa45a36751ab1c.pdf.

[1]	朱愿超, 张亚同, 胡欣. 老年人用药风险管理原则和措施[J]. 中国药物警戒, 2023, 20(9): 1031-1034.
[2]	朱愿超, 赵明, 胡欣, 施红. 药师主导老年多重用药患者管理的思考和实践[J]. 中国药物警戒, 2023, 20(7): 817-821.
[3]	张青霞, 周柳君, 李晓玲, 王育琴. 老年人头孢哌酮舒巴坦用药错误报告分析与建议[J]. 中国药物警戒, 2023, 20(5): 574-578.
[4]	张渊, 贺梅. 1例盐酸曲美他嗪片致合并肾功能不全老年患者帕金森综合征的药学监护[J]. 中国药物警戒, 2023, 20(3): 343-345.
[5]	孙健, 刘子维, 刘莹, 张美玉, 李孟莹, 张海鸣, 聂颖兰, 权建野, 闫寒, 彭娟, 栗俞程, 杨书彬. UPLC-Q-TOF-MS^E技术结合UNIFI筛查平台分析加味逍遥丸化学成分[J]. 中国药物警戒, 2023, 20(2): 181-190.
[6]	田春华, 吴桂芝. 定期获益-风险评估报告在我国的实施思考[J]. 中国药物警戒, 2023, 20(12): 1382-1384.
[7]	贾晋生, 王青, 刘红亮, 侯永芳. 药品上市许可持有人药物警戒工作评估指标体系的探索[J]. 中国药物警戒, 2023, 20(10): 1090-1094.
[8]	黄艳丽, 谢雁鸣, 王连心, 孙粼希, 刘峘, 庄鋆妮. 真实世界老年患者使用刺五加注射液的临床分析[J]. 中国药物警戒, 2022, 19(9): 935-939.
[9]	褚燕琦, 江永贤, 沈江华, 邢晓璇, 张青霞, 闫素英. 老年患者胸腔镜术后镇痛使用风险调查及防范[J]. 中国药物警戒, 2022, 19(9): 1023-1026.
[10]	董晗硕, 孙莉, 赵晓晓, 王连心, 余小康, 谢雁鸣. 真实世界榄香烯乳状注射液用于老年人群的临床特征及联合用药分析[J]. 中国药物警戒, 2022, 19(8): 845-850.
[11]	马冰冰, 张晓朦, 张冰, 林志健, 吕锦涛. 基于文献分析的老年人中成药合理用药与药学服务思考[J]. 中国药物警戒, 2022, 19(6): 595-599.
[12]	柴晓利, 张臣, 丰庆春, 刘欢. 非瓣膜性心房颤动老年患者用药现状及影响因素分析[J]. 中国药物警戒, 2022, 19(3): 302-305.
[13]	朱玉婷, 李茂星. 甲巯咪唑片致粒细胞缺乏1例分析[J]. 中国药物警戒, 2022, 19(3): 345-348.
[14]	孙粼希, 谢雁鸣, 黎元元, 孙梦华, 李向杰. 真实世界2247例应用连花清瘟胶囊的老年患者用药模式分析[J]. 中国药物警戒, 2022, 19(1): 32-35.
[15]	孙春全, 谢雁鸣, 侯恒悦. 真实世界生脉注射液治疗9215例老年心血管疾病的临床特征及联合用药研究[J]. 中国药物警戒, 2022, 19(1): 36-40.

基于真实世界数据老年常见病多重用药风险数据管理平台设计与实施

Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics